Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spessotto, P.
Right arrow Articles by Perris, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spessotto, P.
Right arrow Articles by Perris, R.
[Cancer Research 61, 339-347, January 1, 2001]
© 2001 American Association for Cancer Research

Tumor Biology

Laminin Isoforms 8 and 10 Are Primary Components of the Subendothelial Basement Membrane Promoting Interaction with Neoplastic Lymphocytes1

Paola Spessotto, Zhinan Yin2, Gaetano Magro, Rainer Deutzmann, Arlene Chiu, Alfonso Colombatti and Roberto Perris3

Division for Experimental Oncology 2, National Cancer Institute CRO-IRCCS, 33081 Aviano, Italy [P. S., Z. Y., A. Co., R. P.]; Institute of Anatomy and Pathology, University of Catania, 95124 Catania, Italy [G. M.]; Department of Biochemistry, University of Regensburg, D-8400 Regensburg, Germany [R. D.]; The Beckman Research Institute, The City of Hope, Duarte, California 91010 [A. Ch.]; Dipartimento di Scienze e Tecnologie Biomediche, University of Udine, 33100 Udine, Italy [A. Co.]; and Department of Evolutionary and Functional Biology, University of Parma, 43100 Parma, Italy [R. P.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
To determine whether subendothelial laminins (LNs) could be implicated in the extravasation of neoplastic lymphocytes, we have examined the distribution of a number of LN isoforms in human vascular structures of adult individuals and have assayed the ability of the isolated LN molecules to promote adhesion of lymphoma and leukemic cells in vitro using a novel cell adhesion assay, CAFCA, Centrifugal Assay for Fluorescence-based Cell Adhesion (E. Giacomello et al., Biotechniques, 26: 758–762, 1999; P. Spessotto et al., Methods Mol. Biol., 139: 321–343, 2000). The use of previously characterized LN chain-specific antibodies showed that the vast majority of the smaller vascular compartments, known to correspond to sites of lymphocyte transmigration, expressed the subunits involved in the structuring of 9 of the 12 LN isoforms known to date. Eight LN isoforms (i.e., LN-1, -2, -4, -5, -8, -9, -10, and -11) and four naturally occurring LN complexes were isolated from various tissues and cultured cells by combined gel filtration, ion exchange, and immunoaffinity chromatographies, and the identity/composition of the isolated LNs/LN complexes was asserted by immunochemical means and amino-acid sequencing. Notwithstanding the widespread colocalization of LN isoforms, a panel of neoplastic B- and T-cell lines and lymphocytes isolated from patients affected by chronic lymphocytic B-cell leukemia attached preferentially and with high avidity to purified LN-8, purified LN-10, and LN-10-containing protein complexes, whereas lymphocytes derived from patients diagnosed with acute lymphocytic leukemia failed to bind to these LNs. All of the tested neoplastic lymphocytes failed to adhere to the isolated LN-1, LN-4, LN-9, and LN-11 and attached moderately well to purified LN-2 and LN-5. The interaction of transformed lymphocytes with LNs was cation-dependent and interchangeably mediated by the {alpha}3ß1 and {alpha}6ß1 integrins. The degree of engagement of the two LN receptors was dependent upon their relative levels of cell surface expression, whereas, irrespective of the phenotype, lymphocytes deprived of either of these receptors were incapable of LN binding. The findings suggest that LN-8 and LN-10 may act in an independent or complementary fashion as primary components of the endothelial basement membrane favoring the interaction of extravasating neoplastic lymphocytes. Thus, our results would demonstrate that different LN isoforms may evoke diverse cellular responses in different cell types and that this divergence may be the basis for the redundancy of LN distribution in a number of vascular structures.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The phenomenon of intravasation and extravasation of normal and neoplastic lymphocytes is known to involve intimate interactions with both the subendothelial basement membrane and its underlying connective tissue ECM (1) .4 In particular, the transversing of the former acellular structure is considered to be a critical step in both the ingression and egression of the cells from the blood stream, which in turn is a prerequisite for the invasion of the surrounding connective tissues during inflammatory conditions or uncontrolled dissemination of neoplastic cells. The interaction of neoplastic human lymphocytes (mainly T-cell lymphomas and leukemia) with various basement membrane components has been examined previously (2, 3, 4, 5, 6, 7) in vitro in the effort to disclose the key molecule(s) responsible for the trans-endothelial passage of the cells. Originally, two primary basement membrane components that included EHS laminin-1 (LN-1), which has conventionally been adopted as a model LN-1 in the absence of alternative purified LN-1 molecules derived from higher mammals, and collagen type IV were identified as potential lymphocyte ligands. However, a significant involvement of these ECM components in the intravasation/extravasation process could largely be rejected on the basis of their inability to mediate lymphocyte attachment in the absence of artificial activation of the cells with phorbol esters, mitogens, cytokines, anti-CD3 antibodies, or anti-ß1 integrin-activating antibodies (2, 3, 4, 5, 6, 7) . On the other hand, an early study indicated that an epithelial basement membrane component denoted "epiligrin" and now known to correspond to a LN-5/LN-6/LN-7 complex could function as a putative attachment-promoting factor for skin-homing T-cell lymphomas (8) . A certain preference for LN-8 and LN-10 has been proposed recently for normal hematopoietic progenitor cells of the murine bone marrow where these isoforms appear to prevail as cell-interactive ones (9) .

Three plausible arguments may be put forward to explain the previously reported inability of both activated lymphocytes, e.g., those engaged in inflammatory processes, and neoplastic lymphocytes that exhibit a diffuse tissue spreading to interact with LN-1. First, sporadic analyses of the single LN chains expressed in fetal and adult human blood vessels, murine bone marrow, developing murine endothelia, and cultured mammalian endothelial cells have identified LN-8, LN-9, LN-10, and LN-11 as the primary LNs produced by the endothelium (9, 10, 11, 12, 13) . In contrast, LN-2 and LN-4 appear to be weakly expressed or to be deposited exclusively in the more distal layers of the blood vessel wall, such as within the pericyte and smooth muscle layer (media-adventitia) of larger arteries (14 , 15) . It has also been postulated that {alpha}1-containing isoforms may be scarcely represented during embryonic vasculogenesis (11 , 14 , 15) and in the adult vascular tissues (16) , being prevalently expressed in capillaries and smaller vessels (17) . The {alpha}3-containing LNs, i.e., LN-5, LN-6, and LN-7, are thought to be largely absent from most adult vascular compartments and may only be found in fetal blood vessels and vascular structures of lymphoid tissues such as thymus and spleen (13 , 18, 19, 20, 21, 22) . Secondly, observations made on cultured cells suggest that EHS LN-1 could represent an "unusual LN-1" which because of its aberrant tumor-related glycosylation traits could be incapable of functioning as a universal cell-binding LN (23) . Finally, the possibility has been raised that LNs may not be involved in the process of lymphocyte transmigration of the blood vessel wall, which, conversely, may be mediated primarily by other basement membrane components.

Thus, to define the potential role of LNs in the process of intravasation/extravasation of malignant lymphocytes, as well as identify the isoforms involved in this process, we have reexamined the distribution of LNs in vascular structures of adult human tissues and have probed the ability of purified LNs to promote adhesion of neoplastic B and T lymphocytes in vitro. Our data reveal a considerable redundancy in the LN isoforms deposited in the basement membranes of these structures and identify isoforms 8 and 10 as the candidate LNs responsible for the interaction of human neoplastic lymphocytes with the basal endothelial ECM of capillaries and smaller vessels. Thus, we propose that these LNs may represent key molecules involved in the ingress/egress of these cells from the blood and lymphatic circulation.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies and Other Reagents.
A number of well-described anti-laminin polyclonal and mAbs were used in conjunction with two recently produced mAbs and one polyclonal antiserum (Table 1)Citation . If not otherwise stated, production and specificity of the mAbs can be obtained from the commercial source or from previous publications of the providers. Thus, mAbs 4C7 (anti-{alpha}5), 5H2 (anti-{alpha}2), 4E10 (anti-ß1), 2E8 (anti-{gamma}1), P3H9–2 (anti-{alpha}3), and MAB1904 (anti-ß1) were purchased from Chemicon International (Temecula, CA). The murine hybridoma clone that produces mAb C4 (anti-ß2) was obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA). Polyclonal antibodies 310 (anti-{alpha}2) and 317 (anti-{alpha}1) were obtained from Lydia Sorokin (Department for Experimental Medicine, University of Erlangen-Nurnberg, Erlangen, Germany) and are cross-reactive with mouse, rat, bovine, and human LN chains. mAbs BM165 (anti-{alpha}3) and K140 (anti-ß3) were provided by Patricia Rousselle (Institute de Biologie et Chimie des Proteines, Centre National de la Recherche Scientifique, Lyon, France) and Robert E. Burgeson (The Cutaneous Biology Research Center). mAbs 20H2 (anti-collagen type XII) and 15B8 (anti-collagen type XIV) were obtained from Claire Letthias (Institute de Biologie et Chimie des Proteines, Centre National de la Recherche Scientifique, Lyon, France). mAbs 652C4 and 652B2 against the human {alpha}4 LN chain were produced by conventional procedures by immunization of BALB/c mice with recombinant fragments corresponding to the COOH-terminal G1–G3 domains of the human {alpha}4 laminin chain. The selection and characterization of hybridoma clones were carried out by using various immunochemical assays that involve the diverse LN and collagen preparations as antigens. These mAbs do not react with the corresponding recombinant G1–G3 fragments of {alpha}1, {alpha}2, {alpha}3, and {alpha}5 human LN chains (data not shown). A rabbit polyclonal antiserum against the human laminin {alpha}5 chain was obtained from Marie-France Champliaud (The Cutaneous Biology Research Center, Harvard Medical School, Charlestown, MA). This antiserum does not cross-react with other {alpha} chains, and as found here, it does not recognize the ß1, ß2, and {gamma}1 chains. Polyclonal antisera against the recombinant COOH-terminal G1–G5 domains of mouse {alpha}1 chain (As126.46) and against the EHS LN-1-nidogen complex were produced in rabbits according to standard protocols. ELISA and immunoblotting experiments show that the anti-{alpha}1 antiserum As126.46 does not react with human LN-2/(4) , LN-5, LN-8, LN-9, LN-10, and LN-11 (Fig. 1Citation ; data not shown). The antimurine LN-1-nidogen complex antiserum recognizes human and bovine ß1 and {gamma}1 chains and nidogen but fails to react with LNs containing the {alpha}2, {alpha}3, {alpha}4, {alpha}5, ß2, ß3, and {gamma}2 subunits (Refs. 24, 25, 26, 27 ; data not shown).


View this table:
[in this window]
[in a new window]
  		Table 1 Antibodies to LN subunits and collagens

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 1. ELISA with the anti-{alpha}1 antiserum 126.46 on various purified LNs.

 
Antibodies to integrins were obtained as follows: anti-{alpha}3 clone F4 from Luciano Zardi (Istituto Tumori, Genova, Italy); anti-{alpha}1 (clone TS2/7) from Martin E. Hemler (Dana-Farber Institute, Boston, MA); anti-{alpha}1 (clone 1B3.1) from Ilam Bank (The Chaim Sheba Medical Center, Tel Aviv University, Israel); anti-{alpha}2 (clone 12F1) from Virgil Woods (Lombardi Cancer Research Center, Georgetown University, Washington, DC); anti-{alpha}v from Robert Pytela (Section for Cardiovascular Research, University of California, San Francisco, CA); anti-{alpha}6 (clone GoH3) from Arnoud Sonnenberg (Division of Cell Biology, the Netherlands Cancer Institute, Amsterdam, the Netherlands); anti-{alpha}3 (clone P1B5), anti-{alpha}3ß1 complex (clone M-KD102), and anti-{alpha}2ß1 complex (clone JBS2) from Chemicon International; and anti-ß1 (clone 4B4) from Coulter Scientifics (San Francisco, CA).

Immunohistochemistry.
Healthy human tissues were obtained from various carcinoma, sarcoma, and cutaneous melanoma specimens removed by surgery from patients received for diagnosis and/or treatment at the Institute of Anatomy and Pathology, University of Catania, and at the National Cancer Institute, CRO-IRCCS, Aviano. Tissues surrounding the tumor lesion were dissected out, asserted by morphological criteria to be nontransformed, and frozen immediately in liquid nitrogen. Frozen specimens were embedded in OCT compound and cryosectioned. Immunohistochemistry was carried out by sequential incubation with primary and secondary antibodies and detection through the streptavidin-biotin complex kit (LSAB; Dakopatts, Copenhagen, Denmark), followed by counterstaining with H&E.

SDS-PAGE and Immunoblotting.
LN preparations (see below) were analyzed by SDS-PAGE under reducing and nonreducing conditions using 3–8% and 3–10% gradient gels and Coomassie Brilliant Blue or silver staining. For immunoblotting, resolved proteins were electrotransferred onto nitrocellulose membranes, which were subsequently saturated with PBS containing 1% {alpha}-casein for 2 h at room temperature and incubated with primary antibodies at 4°C overnight. After extensive washing in PBS-0.1% {alpha}-casein, the membranes were incubated with horseradish peroxidase-conjugated antirabbit, antirat, or polyvalent antimouse immunoglobulin antibodies and then revealed with the Enhanced ChemiLuminescence Plus chemiluminescence kit (Roche Molecular Biochemicals).

Amino Acid Sequence Analysis.
The LN complex from adult bovine kidney (see below) was resolved by SDS-PAGE on 3–8% gradient gels, and the separated polypeptides were electroeluted for further digestion with the lysine-specific protease from Achromobacter (Wako, Germany) for 6 h at 30°C in 50 mM Tris-HCl buffer (pH 9.0), using 4 µg of protease/200 µg of protein. The peptides were separated by reversed phase chromatography on a Vydac C-18 column (0.2 x 20 cm) using a linear 0–70% gradient of aqueous acetonitrile in 0.1% trifluoroacetic acid, collected, and sequenced.

Purification and Characterization of Single and Complexed LNs.
Native LN-1-nidogen complex from EHS mouse tumor and LN-2/4 complexes from human placenta and bovine heart were purified by a previously described EDTA-extraction procedure (24, 25, 26 , 28) . Comparative densitometric analysis of Western blotting-matched Coomassie Blue-stained bands SDS-PAGE gels, aimed at defining the relative ratios of {alpha}, ß, and {gamma} chain components in LN complexes, showed a significantly higher ratio of ß2 in the bovine heart LN than in the placental one. This suggested a significantly higher relative amount of LN-4 in the former complex. We therefore refer to the vascular LN complexes from placenta and heart as LN-2/(4) (human placenta) and LN-2/4 (bovine heart), respectively. Another mouse heart LN-2/4 complex similar to that of bovine was kindly provided by Lydia Sorokin. LN-5 (also known as kalinin) isolated from cultured human keratinocytes through immunoaffinity chromatography on mAb BM165 (29) was kindly provided by Patricia Rousselle. Chick heart LN-2, LN-4, and LN-9, the latter two provided by Ralph Brandenberger and Matthias Chiquet (M. E. Muller Institute for Biomechanics, Bern, Switzerland), were purified from EDTA extracts by sequential lectin and immunoaffinity chromatographies on columns containing antichick ß1 chain (mAb 11B2) antibodies, antichick {alpha}2 chain (mAb 8D3) antibodies, and the anti-ß2 chain mAb C4 (30, 31, 32) . Pepsin-extracted human placenta, affinity-purified on columns that contained mAb 4C7, was purchased from Chemicon International. Although a previous publication (33) indicated that this immunoaffinity purification protocol yields a mixture of LN-10 and LN-11, our data, based upon immunochemistry and amino acid sequencing of polypeptides resolved by SDS-PAGE, show that the preparation used in this study is composed exclusively of LN-10.5 LN-11 was purified from cultured rat RN22 Schwannoma cells as previously described (34 , 35) .

A naturally occurring LN complex present in adult bovine kidney was received from Anders Lindblom, Mats Paulsson, and Ralph Broermann (Department of Biochemistry, University of Cologne, Germany) and purified in the laboratory according to minor modifications of a previously published protocol (27) . Rat yolk sac LN was purchased from Chemicon International. Nidogen-free EHS LN-1, human plasma fibronectin, and rat tail collagen type I were purchased from Collaborative Research Biochemicals. Purified collagen type XII was obtained from Claire Letthias, and a mixture of collagen type XII and XIV was obtained from the differential elution of CM-cellulose columns during the purification of the bovine kidney LN complex (27) . LN-8 was purified from cultured bovine aorta endothelium cells as previously described (10 , 11) . Consistent with previous observations, ELISA, SDS-PAGE, and Western blotting experiments with anti-{alpha}5 and anti-ß2 chain antibodies confirmed here that endothelium-derived LN-8 was free of LN-9-LN-11 (data not shown).

Cells and FACS Analysis.
The lymphocyte lines Karpas 299 (T-cell lymphoma), HUT78, HUT102 (cutaneous T-cell lymphoma), CEM (T-cell lymphoma), Molt-4, Jurkat (T-cell leukemia), Raji, Ramos and Sc-1 (Burkitt type lymphoma), Ri-1 (large nonconvoluted B-cell lymphoma), BV-173 (B-lymphoid blast crisis of a chronic myeloid leukemia), and Ci-1 (B-cell lymphoblastic lymphoma) were grown in RPMI 1640 medium supplemented with 10–15% FCS. The sarcoma cell lines HT1080 (fibrosarcoma), RD-kD (rhabdomyosarcoma), SK-LMS-1, SK-UT-1, and MES-SA (leiomyosarcoma) were grown in DMEM supplemented with 10% FCS. Peripheral B lymphocytes were isolated after informed consent from patients affected by CLL or ALL and referred to the Department of Hematology and Oncology of the National Cancer Institute, CRO-IRCCS, Aviano. For flow cytometric analysis of integrin expression by indirect immunofluorescence, cells were washed in PBS with 5 mM EDTA and incubated with primary antibodies in PBS with 5 mM EDTA and 0.01% NaN3 for 45 min on ice, followed by washing and incubation with secondary immunoglobulin-species specific antibodies for 30 min on ice. Antibody-labeled cells were fixed and examined for surface fluorescence in a FACScan flow cytometer, and the data were analyzed with the Lysis II program (Becton Dickinson).

Cell Adhesion Assay (CAFCA).
Despite of the previously documented cell-binding activity of the single LN isoforms and LN complexes used in this study, we initially ascertained the ability of these LNs to support adhesion of well-established LN-binding cells. Details of the cell adhesion assay CAFCA used in this study have been provided in previous publications (36, 37, 38) . A series of tests were initially carried out to determine the minimal reverse centrifugal force required to detach cells adhering nonspecifically to BSA yet sufficiently low to detect specific low-avidity interactions with LNs. This minimal force was established to be 12 x g for all cell lines when applied for 5 min at 37°C, whereas the optimal force for ex vivo CLL and ALL cells was found to be 42 x g. Another series of experiments, in which the CAFCA miniplate assemblies were centrifuged at 12, 45, 100, 177, 399, and 740 x g, were carried out with the aim of determining the relative strength of cell adhesion to the various LN substrates (see below). Fibronectin was consistently used as a reference adhesion-promoting molecule. The relative number of cells bound to the substrate (i.e., remaining bound to the bottom miniplates) and cells that fail to bind to the substrate (i.e., remaining in the wells of the top miniplates) were estimated by top/bottom fluorescence detection in a computer-interfaced SPECTRAFluor Plus microplate fluorometer (TECAN, AG, Ropperswit, Switzerland). Fluorescence values were elaborated by the CAFCA software (TECAN) to determine the percentage of adherent cells out of the total cell population analyzed, according to a previously published formula (36 , 38) . Relative strengths of cell adhesion in dynes/cell (Afd) were calculated as previously described according to the formula: Afd = (Dc - Dm) x Vc x Fc, where Dc is the specific density of the cell, previously established to be 1.07 g/cm3 (36) ; Dm is the specific density of the medium = 1.00 g/cm3; Vc is the volume of the cell; and Fc is the centrifugal force exerted on the bound cell. The average cell diameter was estimated to be 12 µm. Statistical significance was determined by Student’s t test with the significance limit set at P < 0.001.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Distribution of LN Subunits in Adult Human Vascular Tissues.
A panel of anti-LN antibodies with previously documented specificity and/or with reactive patterns established herein (Table 1)Citation was used immunohistochemically to determine the in situ distribution of various LN isoforms in vascular structures of 11 representative adult tissues, which included skin, thyroid, placenta, kidney, skeletal muscle, spleen, endometrium, mammary gland, lung, colon, and stomach. With the exception of larger veins and arteries and irrespective of the type of vascular structure, i.e., smaller capillaries, arterioles, or postcapillary venules, subunits that compose 9 of the 12 currently known LN isoforms (i.e., LN-1–5 and LN-8–11) were detected with the chain-specific antibodies in coincident patterns in the majority of the studied tissues. Representative stainings obtained for {alpha}1-{alpha}5, ß1, ß3, and {gamma}1 chains are shown in Fig. 2Citation . Small- and medium-sized arteries of lung and skin failed to express {alpha}3 and ß3, as indicated by the lack of reactivity with mAb K140 and BM165, respectively (Fig. 2)Citation . Similarly, {alpha}2 expression was not observed in capillaries of the kidney cortex glomerular capsules and in vascular structures of the lung (data not shown). This suggests that, at least in humans, adult and fetal blood vessels may differ and may exhibit a LN isoform composition divergent from that of the vasculature of lower mammals. Our data on the relative widespread distribution of the LN-1 in vascular basement membranes differ somewhat from that recently reported (17) using {alpha}1 subunit-specific mAbs and showing a more restricted expression of this chain to smaller capillaries. The reason for this discrepancy is presently unclear but may be associated with differential masking effects that impair full recognition of certain partially buried {alpha}1 chain epitopes.



View larger version (150K):
[in this window]
[in a new window]
  		Fig. 2. Immunohistochemical distribution of various LN subunits in vascular structures of human adult lung, thyroid, skin, and mammary gland. Note the lack of {alpha}3 expression in medium-sized arteriole of the lung, whereas {alpha}1 and {alpha}4 were widely distributed in all blood vessels of this organ. In the thyroid, the epithelial basement membranes do not express {alpha}3-containing LN isoforms (not shown) but contain subunits that constitute the other isoforms. Mammary glands expressed all of the examined LN subunits in the different vascular compartments.

 
Characterization of Isoform 10-containing LN Complexes.
The heterogeneous LN complex isolated from adult bovine kidney (27 , 39 , 40) was characterized further by biochemical and immunochemical means. Amino acid sequences that were derived from 14 different high-performance liquid chromatography-separated tryptic peptides generated from the putative {alpha} chain bands of this LN complex and running on SDS-PAGE under reducing conditions in the range of Mr 350,000–400,000 indicated the presence of the {alpha}1 and {alpha}5 LN subunits, as well as Col XII as a primary non-LN contaminant (Fig. 3)Citation . Immunoblotting of this complex with chain-specific anti-LN antibodies both asserted the presence of LN {alpha} subunits and, in accordance with previously published observations (39 , 40) , identified the {alpha}5 subunit as the molecular species migrating at about Mr 370,000–380,000 (Fig. 3)Citation . In contrast, no {alpha}3 or {alpha}4 LN subunit could be detected, whereas Col XII but not Col XIV was confirmed immunochemically to be associated with this LN complex (Fig. 3)Citation . The relative ratio of the two identifiable {alpha} chain components, i.e., {alpha}1 and {alpha}5, was technically impossible to establish because the isoforms that contained these subunits were not completely separable one from another. However, data obtained by immunoblotting and densitometric analysis of the {alpha}1/Mr 400,000 and {alpha}5/Mr 370,000–380,000 Coomassie blue-stained bands suggested that the {alpha}1 prevailed over the {alpha}5 subunit. Thus, collectively, our observations provide a further characterization of this LN complex (27 , 40) and indicate that it is composed of a mixture of LN-1, LN-10, and LN-11. Immunoblotting of this complex with the anti-{alpha}5 chain antiserum also disclosed a Mr 200,000 polypeptide (Fig. 3)Citation . Bands that migrate below Mr 300,000 have been identified in other tissue-derived putative LN-10/LN-11 complexes (32 , 41) but not in immunopurified LN-10 preparations (39 , 42) , suggesting that the Mr ~200,000 polypeptide may correspond to a naturally occurring proteolytic fragment of the tissue form of the {alpha}5 LN subunit. This fragment may also be found in LN-11-containing preparations, as suggested by the fact that LN-11 isolated from RN22 Schwannoma cells and {alpha}5-containing LNs from astrocytoma cells both exhibit "Y-shaped" configurations (33 , 34 , 43 , 44) , which resemble those observed for the bovine kidney LN complex (27) .



View larger version (68K):
[in this window]
[in a new window]
  		Fig. 3. Left panel shows a silver staining of the bovine kidney LN-1/10/11 complex resolved on a 3–8% gradient SDS-PAGE gel under reducing and nonreducing conditions. Nidogen-free EHS LN-1 was used as reference. Representative amino acid sequences of tryptic peptides derived from the corresponding bands are indicated to the right. Lower right panel shows immunoblotting of the bovine kidney LN-1/10/11 and rat yolk sac LN-1/(10) complexes with antibodies to {alpha}1 (anti-{alpha}1), {alpha}5 (anti-{alpha}5), {alpha}3 (mAb BM165), {alpha}4 (mAb 652B2), collagen type XII (mAb 20H2), and collagen type XIV (mAb 15B8).

 
Our immunochemical data on the previously described rat yolk sac LN (45, 46, 47) suggest that it corresponds to a mixture of LN-1 and LN-10, as shown by positive immunoreaction of antisera against the {alpha}1 and {alpha}5 subunits with the Mr 400,000 and Mr 370,000–380,000 bands (Fig. 3)Citation . In analogy with the LN complex from the kidney, a putative Mr 200,000 {alpha}5 fragment could be detected in this preparation (Fig. 3)Citation . Because Western blotting with anti-{alpha}1 and anti-{alpha}5 antisera suggested a prevalence of LN-1 (Fig. 3)Citation , we refer to this nidogen-free complex as LN-1/(10) .

Elective High-affinity Adhesion of Neoplastic Lymphocytes to Vascular LN-8 and LN-10.
To determine the capability of neoplastic lymphocytes to interact with vascular LNs and the possible isoform preference of this interaction, we compared the ability of the various unstimulated neoplastic lymphocyte types to adhere to the panel of purified LNs (using fibronectin as reference adhesion-promoting molecule). Lymphocytes largely failed to bind to LN-1, LN-4, LN-9, and LN-11, bound weakly to moderately well to LN-2, LN-5, and LN-8, and attached to LN-10 to a similar or higher extent as to fibronectin (Table 2)Citation . A similar high-avidity binding was observed to the bovine LN-1/10/11 complex (Fig. 4)Citation , which suggested that the apparently lower amounts of the largely inactive LN-1 and LN-11 did not counteract the adhesion-promoting activity of LN-10. In contrast, LN-1/(10) from rat yolk sac and LN-2/4 complexes from human placenta and bovine heart were significantly less effective than the purified isoforms, i.e., LN-2 and LN-10, and than complexes in which the active LNs predominated, i.e., LN-2/(4) and LN-1/10/11 (Fig. 4)Citation . Apart from LN-4 and LN-11, proposed to play solely an important role in the promotion of neurite outgrowth, all of the LNs that showed a weak ability to support lymphocyte adhesion actively sustained attachment of human sarcoma cells. This finding indicates that LNs unable to mediate significant adhesion of neoplastic lymphocytes did not lack a generalized capability to bind cells.


View this table:
[in this window]
[in a new window]
  		Table 2 Interaction of tumor lymphocytes with isolated laminin isoformsa

 


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 4. Adhesion profiles of neoplastic lymphocytes binding to the different naturally occurring LN complexes.

 
Some differences were noted in the cell-LN interaction between the different lymphocyte types. Leukemic and lymphoma T cells pronouncedly attached to LN-2 and LN-5, whereas leukemic B cells and Burkitt-type lymphomas were ineffective in binding to these isoforms. The superior ability of LN-10 to promote neoplastic lymphocyte adhesion was also demonstrated by the relative higher cell-binding avidity displayed by both T and B neoplastic lymphocytes to this LN isoform. In fact, when compared, the avidity of lymphocyte adhesion to LN-10 and LN-1/10/11 was 2–4-fold higher than to LN-2/(4) and LN-5, and the average relative force necessary to detach cells from the LNs was estimated to be Afd of <=7 x 10-9 versus Afd of <=2 x 10-7 dynes/cell for LN-10/LN-1/10/11 and LN-2/(4) /LN-5, respectively (Fig. 5)Citation . Lymphocyte binding to LNs was entirely cation-dependent and was promoted by physiological concentrations of Mg2+ (0.3–3 mM) and Mn2+ (0.1–30 µM) but not Ca2+ (data not shown).



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 5. Comparison of the relative binding affinity of representative T and B neoplastic lymphocytes with LN-10 and versus other LNs, as determined by CAFCA. Centrifugal forces above 760 x g were not possible to apply because they were found to damage the cells.

 
To establish whether the observed LN isoform preferences exhibited by the neoplastic cell lines were representative also for lymphocytes derived from patients with hematological malignancies, we examined the ability of peripheral lymphocytes isolated from CLL and ALL patients to interact with the various LNs. Although showing some variability, B lymphocytes from CLL patients attached well to LN-8, LN-10, and the LN-1/10/11 complex, with the adhesion capability of cells from the different patients being closely related to the overall ability of the cells to recognize LNs (Table 3)Citation . On the other hand, ALL lymphocytes that completely lacked LN-binding integrins or that showed weak expression of these receptors bound significantly more poorly to the isolated LN-8 and LN-10 but still adhered to LN-1/(10) and LN-1/10/11 complexes (Table 3)Citation .


View this table:
[in this window]
[in a new window]
  		Table 3 Adhesion of lymphocytes from ALL/CLL patients to LN isoformsa

 
Integrin Receptors Mediating Lymphocyte Adhesion to LNs.
Lymphocyte adhesion to all LNs tested herein was completely blocked by anti-ß1 integrin subunit antibodies but was unaffected by antibodies to ß3 and ß5 subunits (not shown). A similar strong reduction in lymphocyte attachment to LNs was seen after the addition of antibodies to either the {alpha}3 or {alpha}6 integrin subunit and/or against the {alpha}3ß1 complex but not by antibodies to {alpha}1, {alpha}v, {alpha}2, and {alpha}2ß1 integrin subunit/complex (Fig. 6)Citation . Affinity chromatography of iodinated Karpas 299 and Jurkat cell membranes on immobilized LN-1, LN-2/(4) , and LN-1/10/11 confirmed the high-affinity binding of the {alpha}3ß1 (on Karpas 299) and {alpha}6ß1 (on Jurkat) integrin receptors, because these were specifically eluted with EDTA from columns containing LN-2/(4) and LN-1/10/11 but not LN-1 (not shown).



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 6. Summary of the effects of anti-{alpha}3 (unfilled symbols) and anti-{alpha}6 (filled symbols) integrin antibodies on T and B neoplastic lymphocyte adhesion to purified LN isoforms and LN complexes. Data are expressed as percentage of cell binding in the presence of the blocking anti-integrin antibodies when compared with cell binding observed after the addition of nonblocking antibodies or antibodies against irrelevant integrin {alpha} subunits. Antibodies to ß1-integrin (mAb 4B4) completely inhibited cell adhesion, i.e., >80% blockade. Cells are grouped according to their relative surface expression of LN-binding integrin receptors as independently determined by FACS analysis. The behavior of the cells assayed is shown collectively because cell attachment was either significantly affected or significantly unaffected by antibody addition, and differences among the antibody blockades within the same group of cells (i.e., upper, middle, or lower graph) were not significantly different. Values are means of quadruplicate experiments yielding an SD <20%.

 
As shown by antibody blockade experiments and FACS analyses, utilization of {alpha}3ß1 or {alpha}6ß1 integrins for lymphocyte interaction with LN-2, LN-5, LN-8, and LN-10 was strictly dependent upon which of the integrins prevailed on the cell surface. However, the {alpha}6ß1 integrin consistently dominated over the {alpha}3ß1 in mediating LN binding, even when present in apparently lower relative amounts. Thus, Karpas 299, HUT78, HUT102, Ri-1, Sc-1, and Ci-1 showed high expression of {alpha}3ß1 and no detectable surface expression of {alpha}6ß1, and these cells used the former integrin receptor for binding to all interactive LN isoforms. On the other hand, Jurkat, Molt-4, Raji, Ramos, and BV-173 cells expressed superior levels of {alpha}6ß1 than {alpha}3ß1, and in these cases the LN interaction was dictated by the former integrin. An interesting correlate was that only cells that expressed substantial amounts of {alpha}6ß1 exhibited a weak binding to LN-1 (e.g., Jurkat and Raji cells; Table 2Citation ), indicating that {alpha}6ß1 may be a universal and genuine LN-1-binding integrin.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
To elucidate the role of subendothelial LNs of capillaries and smaller vessels in the neoplastic lymphocyte intravasation/extravasation phenomena, we have: (a) mapped the distribution of the subunits composing 9 of the 12 putative LNs known to date in a number of representative adult healthy human tissues/organs; (b) characterized biochemically and immunochemically isolated LNs and LN complexes derived from highly vascularized tissues; and (c) comparatively examined the ability of these LNs to promote attachment of lymphocyte lines and lymphocytes isolated from leukemic patients. We find that, despite the fact that virtually all of the subunits examined here codistributed in the smaller vessels corresponding to sites of lymphocyte intravasation/extravasation, LN-10 and, to a lesser extent, LN-8 prevailed in their ability to interact with neoplastic lymphocytes. This finding strongly suggests that these LN isoforms may represent primary lymphocyte ligands of the subendothelial zone. The reason for the excessive redundancy in the tissue compartmentalization of LNs in the adult human body is presently unclear, but the observation strongly suggests a well-articulated functional diversity of the various isoforms in these tissue compartments. In light of previous observation in embryonic and adult mouse tissues, this observation also emphasizes marked differences in LN distributions in vascular structures of lower mammals and man.

Assignment of LN-8 and LN-10 as the candidate components that govern neoplastic lymphocyte interaction with the subendothelium was made possible through the combined immunolocalization of these isoforms in the corresponding basement membrane of adult human tissues and via the utilization of a number of purified LNs and LN complexes with asserted composition. In particular, the isolation and characterization of ß1-containing isoforms (i.e., LN-1, LN-2, LN-8, and LN-10) and ß2-containing isoforms (i.e., LN-4, LN-9, and LN-11) were instrumental in the discrimination of the lymphocyte responses to the major vascular LNs. Different B and T neoplastic lymphocytes bound avidly to LN-2, LN-5, LN-8, and LN-10 in a cation-regulated manner but largely failed to attach to LN-1, LN-4, LN-9, and LN-11. Similar observations had been made earlier when examining the LN-binding ability of ex vivo lymphocytes derived from patients affected by CLL-B (36) , and these findings were extended here by examining lymphocytes derived from an analogous hematological malignancy, i.e., ALL. In these cases, some variation in the binding capability of the cells to LN-8 and LN-10 was noted and was associated with an overall weak capability of cells from certain patients to attach to both LNs and fibronectin. However, inefficient recognition of LNs in these cells appeared to be attributed to a poor cell surface-expression of LN-binding integrins, whereas a certain preferential binding of ALL cells to LN-1/10 complexes indicated a potential cooperative effect of these isoforms in mediating attachment of these specific cell types. The molecular basis for this different behavior of ALL cells was not further investigated here. Taken together, the findings highlight a clear bias of transformed lymphocytes for LNs that contain the ß1/{gamma}1 and {alpha}3-{alpha}5 subunits, which was unlikely to be determined by a loss of biological activity during purification of the less active or completely inactive LN isoforms. This is because LN isoforms tested in this study were ascertained to have retained cell adhesion-promoting activity for selected anchorage-dependent tumor cells, as well as the ability to stimulate neurite outgrowth in vitro.

The marked to complete failure of neoplastic lymphocytes to attach to isolated LN-1 and LN-1-nidogen complexes seemed, on one hand, to be associated with the apparent inability of the {alpha}3ß1 integrin (when present as the primary LN-binding integrin on the cell surface) to recognize this specific isoform and, on the other hand, to be because of an apparent inability of the nonactivated {alpha}6ß1 integrin to mediate the LN interaction with the same efficiency as that observed for mesenchymal/epithelial cells. Despite being widely expressed in vascular tissues, ß2-containing LNs were virtually inactive in supporting neoplastic lymphocyte adhesion. This observation is highly consistent with the preferential ability of LN-4/LN-9/LN-11 to exert a guiding function during embryonic neurite growth in vitro and in vivo (30) but to fail to promote embryonic cell movement in vitro and in vivo (30 , 31) . The use of CAFCA demonstrated a significantly higher avidity binding to the isolated "vascular" LN-10 (and the LN-1/10/11 complex comprised of this isoform) than to the "peri-vascular" LN-5 and LN-2/(4) . This observation raises an interesting point in that, although cells use the same integrin receptors (see below) for recognizing the different LNs, the strengthening of the adhesive responses transduced to cells by these ligands markedly differs.

Static interaction of T and B neoplastic lymphocytes was mediated by both the {alpha}3ß1 and {alpha}6ß1 integrin receptors, depending upon which of these integrins was the prevailing putative LN receptor expressed on the cell surface, with a predominant binding activity exerted by the {alpha}6ß1 integrin. This finding is in disagreement with a previously postulated propensity for an {alpha}3ß1-LN-10 (40) versus {alpha}6ß1-LN-1/LN-8 (48) interaction, but it is in accordance with a recent study on carcinoma cells showing interchangeable utilization of both integrins for the interaction with LN-10 (49) . The observation also affirms that the {alpha}6ß1 may be the primary, universal ß1 LN integrin receptor and that LN-1 may not be a preferred {alpha}3ß1 ligand. The cation requirement for optimal cell attachment to LN-8 and LN-10 largely paralleled that reported for optimal activity of the {alpha}3ß1 integrin when transfected into K562 cells (40) . However, in contrast to this previous report, we do not find evidence that Ca2+ would function in an inhibitory manner for {alpha}3ß1-mediated lymphocyte adhesion to LN. Similarly, we do not find evidence for a high-affinity binding of the {alpha}3ß1 integrin to EHS LN-1 that would be confined to a single linear sequence in the COOH-terminal globules of LNs (50) . First, {alpha}3ß1+/{alpha}6ß1- B and T lymphocytes failed to interact with EHS LN-1 and poorly reacted with the rat yolk sac LN-1/(10) complex. Secondly, manipulation of the tertiary structure of the LN-10 heterotrimer strongly reduced the levels of the {alpha}3ß1-mediated cell adhesion (data not shown). A corollary observation was that refolding (after reversible unfolding) of the LN-1/10/11 complex largely reconstituted the ability of Karpas 299 cells to recognize the complex through their {alpha}3ß1 integrin, which suggests that the nature of its binding site within the LN-10 may be different than that previously identified for the fibrosarcoma and glioma {alpha}6ß1 integrin in EHS LN-1 (51) .

In conclusion, our observations reiterate in a different paradigm the previously postulated nonpermissive effects of LN-1 and ß2-containing LN isoforms on adhesion of certain cell types that still express the adequate LN-binding integrin receptors and emphasize de novo a function for LN-8 and LN-10 in promoting lymphocyte-subendothelium interactions. Thus, the observations suggest the existence of positive and negative controls operated by different codistributed LN isoforms on different cell adhesion phenomena.


   ACKNOWLEDGMENTS
 
We are indebted to Drs. Ralph Brandenberger, Ralph Broermann, Matthias Chiquet, Anders Lindblom, Tracey Marsh, Mats Paulsson, and Patricia Rousselle for contribution with various purified LNs and antibodies, and to Claire Letthias and Lydia Sorokin for anti-collagen and anti-LN antibodies. Drs. Ilam Bank, Martin Hemler, Arnoud Sonnerberg, Virgil Woods, and Luciano Zardi are thanked for providing various anti-integrin antibodies. We are grateful to Antonella Corsaro, Daniela Messina, Maria Teresa Mucignat, and Michela Zambon for their technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Fondo Sanitario Nazionale RF96 and Research Grants from the University of Parma. Back

2 Present address: Section for Rheumatology, Yale University, New Haven, CT 06511. Back

3 To whom requests for reprints should be addressed, at Division for Experimental Oncology, National Cancer Institute Centro di Riterimento Oncologico-Instituto di Ricovero a Cura a Garattere Scientifico, Via Pedemontana Occidentale 12, 33081 Aviano, Italy. Phone: 39-434-659234; Fax: 39-434-659428; E-mail: rperris{at}ets.it Back

4 The abbreviations used are: ECM, extracellular matrix; LN, laminin; mAbs, monoclonal antibodies; FACS, fluorescence-activated cell sorter; CLL, chronic lymphocytic cell leukemia; ALL, acute lymphocytic cell leukemia; CAFCA, centrifugal assay for fluorescence-based cell adhesion; EHS, Engelbreth-Holm-Swarm. Back

5 Spessotto, P., Gronkowska, A., Deutzmann, R., Perris, R., and Colombatti, A. Preferential motility response of neoplastic lymphocytes to laminin isoforms 10, 5, and 8, submitted for publication. Back

Received 2/ 7/00. Accepted 10/25/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brown E. J. Adhesive interactions in the immune system. Trends Cell Biol., 7: 289-295, 1997.[Medline]
  2. Shimuzu Y., van Seventer G. A., Horgan K. G., Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J. Immunol., 145: 59-67, 1990.[Abstract]
  3. Wilkins J. A., Stupack D., Stewart S., Caixia S. ß1 integrin-mediated lymphocyte adherence to extracellular matrix is enhanced by phorbol ester treatment. Eur. J. Immunol., 21: 517-522, 1991.[Medline]
  4. Li Y-Y., Tak Cheung H. T. Basement membrane and its components on lymphocyte adhesion, migration and proliferation. J. Immunol., 149: 3174-3181, 1992.[Abstract]
  5. van de Wiel-van Kemenade E., van Kooyk Y., de Boer A. J., Huijbens R. J. F., Weder P., van de Kasteele W., Melief C. J. M., Figdor C. G. Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the ß subunit of VLA. J. Cell Biol., 117: 461-470, 1992.[Abstract/Free Full Text]
  6. Stoolman L. M., Wang T-L., Situ R., Varani J. Regulation of fibronectin and laminin binding activity in cultured human lymphoblastic cell lines. J. Cell. Physiol., 154: 593-600, 1993.[Medline]
  7. Hershkoviz R., Miron S., Cohen I. R., Miller A., Lider O. T lymphocyte adhesion to the fibronectin and laminin components of the extracellular matrix is regulated by the CD4 molecule. Eur. J. Immunol., 22: 7-13, 1992.[Medline]
  8. Wayner E. A., Gil S. G., Murphy G. F., Wilke M. S., Carter W. G. Epiligrin, a component of epithelial basement membranes, is an adhesive ligand for {alpha}3ß1 positive T lymphocytes. J. Cell Biol., 121: 1141-1152, 1993.[Abstract/Free Full Text]
  9. Gu Y., Sorokin L., Durbeej M., Hjalt T., Jonsson J-J., Ekblom M. Characterization of bone marrow laminins and identification of {alpha}5-containing laminins as adhesive proteins for multipotent hematopoietic FDCP-mix cells. Blood, 93: 2533-2542, 1999.[Abstract/Free Full Text]
  10. Sorokin L., Girg W., Gopfert T., Hallmann R., Deutzmann R. Expression of novel 400-kDa laminin chains by mouse and bovine endothelial cells. Eur. J. Biochem., 223: 603-610, 1994.[Medline]
  11. Sorokin L. M., Pausch F., Frieser M., Kroger S., Ohage E., Deutzmann R. Developmental regulation of the laminin {alpha}5 chain suggests a role in epithelial and endothelial cell maturation. Dev. Biol., 189: 285-300, 1997.[Medline]
  12. Frieser M., Nockel H., Pausch F., Roder C., Hahn A., Deutzmann R., Sorokin L. M. Cloning of the mouse laminin {alpha}4 cDNA. Expression in a subset of endothelium. Eur. J. Biochem., 246: 727-735, 1997.[Medline]
  13. Miner J. H., Patton B. L., Lentz S. I., Gilbert D. J., Snider W. D., Jenkins N. A., Copeland N. G., Sanes J. R. The laminin {alpha} chains: expression, developmental transitions and chromosomal locations of {alpha}1–5, identification of heterotrimeric laminins 8–11, and cloning of a novel {alpha}3 isoform. J. Cell Biol., 137: 685-701, 1997.[Abstract/Free Full Text]
  14. Glukhova M., Koteliansky V., Fondacci C., Marotte F., Rappaport L. Laminin variants and integrin laminin receptors in developing and adult human smooth muscle. Dev. Biol., 157: 437-447, 1993.[Medline]
  15. Durbeej M., Fecker L., Hjalt T., Zhang H-Y., Salmivirta K., Klein G., Timpl R., Sorokin L., Ebendal T., Ekblom P., Ekblom M. Expression of laminin {alpha}1, {alpha}5 and ß2 chains during embryogenesis of the kidney and vasculature. Matrix Biol., 15: 397-413, 1996.[Medline]
  16. Falk M., Ferletta M., Forsberg E., Ekblom P. Restricted distribution of laminin {alpha}1 chain in normal adult mouse tissues. Matrix Biol., 18: 557-568, 1999.[Medline]
  17. Virtanen I., Gullberg D., Rissanen J., Kivilaakso E., Kiviluoto T., Laitinen L. A., Lehto V-P., Ekblom P. Laminin {alpha}1-chain shows a restricted distribution in epithelial basement membranes of fetal and adult human tissues. Exp. Cell Res., 257: 298-309, 2000.[Medline]
  18. Kallunki P., Sainio K., Eddy R., Byers M., Kallunki T., Sariola H., Beck K., Hirvonen H., Shows T. B., Tryggvason K. A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal assignment. J. Cell Biol., 119: 679-693, 1992.[Abstract/Free Full Text]
  19. Gerecke D. R., Wagman D. W., Champliaud M-F., Burgeson R. E. The complete primary structure for a novel laminin chain, the laminin B1k chain. J. Biol. Chem., 269: 11073-11080, 1994.[Abstract/Free Full Text]
  20. Ljubimov A. V., Burgeson R. E., Butkowski R. J., Michael A. F., Sun T-T., Kenney M. C. Human corneal basement membrane heterogeneity: topographical differences in the expression of type IV collagen and laminin isoforms. Lab. Investig., 72: 461-473, 1995.[Medline]
  21. Jaspars L., De Melker A. A., Bonnet P., Sonnenberg A., Meijer C. J. L. M. Distribution of laminin variants and their integrin receptors in human secondary lymphoid tissue. Cell Adhes. Commun., 4: 269-279, 1996.[Medline]
  22. Mizushima H., Koshikawa N., Moriyama K., Takamura H., Nagashima Y., Hirahara F., Miyazaki K. Wide distribution of laminin-5 {gamma}2 chain in basement membranes of various human tissues. Horm. Res. (Basel), 50: 7-14, 1998.
  23. Tanzer M. L., Chandrasekaran S., Dean J. W. , III, and Giniger, M. S. Role of laminin carbohydrates on cellular interactions. Kidney Int., 43: 66-72, 1993.[Medline]
  24. Paulsson M., Aumailley M., Deutzmann R., Timpl R., Beck K., Engel J. Laminin-nidogen complex. Extraction with chelating agents and structural characterization. Eur. J. Biochem., 166: 11-19, 1987.[Medline]
  25. Paulsson M., Saladin K. Mouse heart laminin. Purification of the native protein and structural comparison with Engelbreth-Holm-Swarm tumor laminin. J. Biol. Chem., 264: 18726-18732, 1989.[Abstract/Free Full Text]
  26. Paulsson M., Saladin K., Engvall E. Structure of laminin variants. The 300-kDa chains of murine and bovine hearth laminin are related to the human placenta merosin heavy chain and replace the {alpha} chain in some laminin variants. J. Biol. Chem., 266: 17545-17551, 1991.[Abstract/Free Full Text]
  27. Lindblom A., Marsh T., Fauser C., Engel J., Paulsson M. Characterization of native laminin from bovine kidney and comparison with other laminin variants. Eur. J. Biochem., 219: 383-392, 1994.[Medline]
  28. Ehrig K., Leivo I., Argraves W. S., Ruoslahti E., Engvall E. Merosin, a tissue-specific basement membrane protein, is a laminin-like protein. Proc. Natl. Acad. Sci. USA, 87: 3264-3268, 1990.[Abstract/Free Full Text]
  29. Rousselle P., Aumailley M. Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement for integrin receptors. J. Cell Biol., 125: 205-214, 1994.[Abstract/Free Full Text]
  30. Brandenberger R., Chiquet M. Distinct heparin-binding and neurite-promoting properties of laminin isoforms isolated from chick heart. J. Cell Sci., 108: 3099-3108, 1995.[Abstract]
  31. Brandenberger R., Kammerer R. A., Engel J., Chiquet M. Native chick laminin-4 containing the ß2 chain (s-laminin) promotes motor axon growth. J. Cell Biol., 135: 1583-1592, 1996.[Abstract/Free Full Text]
  32. Perris R., Brandenberger R., Chiquet M. Differential neural crest cell attachment and migration on avian laminin isoforms. Int. J. Dev. Neurosci., 14: 297-314, 1996.[Medline]
  33. Ferletta M., Ekblom P. Identification of laminin-10/11 as a strong cell adhesive complex for a normal and a malignant human epithelial cell line. J. Cell Sci., 112: 1-10, 1998.[Abstract]
  34. Edgar D., Timpl R., Thoenen H. Structural requirements for the stimulation of neurite outgrowth by two variants of laminin and their inhibition by antibodies. J. Cell Biol., 106: 1299-1306, 1988.[Abstract/Free Full Text]
  35. Patton B. L., Miner J. H., Chiu A. Y., Sanes J. R. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J. Cell Biol., 139: 1507-1521, 1997.[Abstract/Free Full Text]
  36. Giacomello E., Neumayer J., Colombatti A., Perris R. Centrifugal assay for fluorescence-based cell adhesion adapted to the analysis of ex vivo cells and capable of determining relative binding strengths. Biotechniques, 26: 758-762, 1999.[Medline]
  37. Spessotto P., Giacomello E., Perris R. Fluorescence assays to study cell adhesion and migration in vitro. Methods Mol. Biol., 139: 321-343, 2000.[Medline]
  38. Yin Z., Giacomello E., Gabriele E., Zardi L., Aota S., Yamada K. M., Skerlavaji B., Doliana R., Colombatti A., Perris R. Cooperative activity of {alpha}4ß1 and {alpha}4ß7 integrins in mediating human B-cell lymphoma adhesion and chemotaxis on fibronectin through recognition of multiple synergizing binding sites within the central cell-binding domain. Blood, 93: 1221-1230, 1999.[Abstract/Free Full Text]
  39. Dogic D., Hülsmann N., Shermann J. W., Fox R., Broermann R., Paulsson M., Aumailley M. Cell adhesion to a population of laminin isoforms isolated from normal renal tissue. Matrix Biol., 18: 433-444, 1999.[Medline]
  40. Delwel G. O., de Melker A. A., Hogervorst F., Jaspars L. H., Fles D. L. A., Kuikman I., Lindblom A., Paulsson M., Timpl R., Sonnenberg A. Distinct and overlapping ligand specificities of the {alpha}3Aß1 and {alpha}6Aß1 integrins: recognition of laminin isoforms. Mol. Biol. Cell, 5: 203-215, 1994.[Abstract]
  41. Kikkawa Y., Sanzen N., Sekiguchi K. Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. J. Biol. Chem., 273: 15854-15859, 1998.[Abstract/Free Full Text]
  42. Tiger C-F., Champliaud M-F., Pedrosa-Domello F., Thornell L-E., Ekblom P., Gullberg D. Presence of laminin {alpha}5 chain and lack of laminin {alpha}1 chain during human muscle development and in muscular dystrophies. J. Biol. Chem., 272: 28590-28595, 1997.[Abstract/Free Full Text]
  43. Church H. J., Aplin J. D. BeWo choriocarcinoma cells produce laminin 10. Biochem. J., 332: 491-498, 1998.
  44. LeMosy E. K., Lightner V. A., Erickson H. P. Structural analysis of a human glial variant laminin. Exp. Cell Res., 227: 80-88, 1996.[Medline]
  45. Engvall E., Krusius T., Wewer U., Ruoslahti E. Laminin from rat yolk sac tumor: isolation, partial characterization, and comparison with mouse laminin. Arch. Biochem. Biophys., 222: 649-656, 1983.[Medline]
  46. Brown J. C., Spragg J. H., Wheeler G. N., Taylor P. W. Identification of the B1 and B2 subunits of human placental laminin and rat parietal-yolk-sac laminin using antisera specific for murine laminin-ß-galactosidase fusion proteins. Biochem. J., 270: 463-460, 1990.[Medline]
  47. Wewer U. M., Tichy D., Damjanov A., Paulsson M., Damjanov I. Distinct antigenic characteristics of murine parietal yolk sac laminin. Dev. Biol., 121: 397-407, 1987.[Medline]
  48. Kortesmaa J., Yurchenco P., Tryggvason K. Recombinant laminin-8 ({alpha}4ß1{gamma}1). J. Biol. Chem., 275: 14853-14859, 2000.[Abstract/Free Full Text]
  49. Tani T., Letho V-P., Virtanen I. Expression of laminins 1 and 10 in carcinoma cells and comparison of their roles in cell adhesion. Exp. Cell Res., 248: 115-121, 1999.[Medline]
  50. Gehlsen K. R., Sriramarao P., Furcht L. T., Skubitz A. P. N. A synthetic peptide derived from the carboxy terminus of the laminin A chain represents a binding site for the {alpha}3ß1 integrin. J. Cell Biol., 117: 449-459, 1992.[Abstract/Free Full Text]
  51. Deutzmann R., Aumailley M., Wiedemann H., Pysny W., Timpl R., Edgar D. Cell adhesion, spreading and neurite stimulation by laminin fragment E8 depends on maintenance of secondary and tertiary structure in its rod and globular domain. Eur. J. Biochem., 191: 513-522, 1990.[Medline]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
G. Gorfu, I. Virtanen, M. Hukkanen, V.-P. Lehto, P. Rousselle, E. Kenne, L. Lindbom, R. Kramer, K. Tryggvason, and M. Patarroyo
Laminin isoforms of lymph nodes and predominant role of {alpha}5-laminin(s) in adhesion and migration of blood lymphocytes
J. Leukoc. Biol., September 1, 2008; 84(3): 701 - 712.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Qian, K. Tryggvason, S. E. Jacobsen, and M. Ekblom
Contribution of {alpha}6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with {alpha}4 integrins
Blood, May 1, 2006; 107(9): 3503 - 3510.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Inoue, K. Suzuki-Inoue, O. J. T. McCarty, M. Moroi, Z. M. Ruggeri, T. J. Kunicki, Y. Ozaki, and S. P. Watson
Laminin stimulates spreading of platelets through integrin {alpha}6beta1-dependent activation of GPVI
Blood, February 15, 2006; 107(4): 1405 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-C. Gu, J. Kortesmaa, K. Tryggvason, J. Persson, P. Ekblom, S.-E. Jacobsen, and M. Ekblom
Laminin isoform-specific promotion of adhesion and migration of human bone marrow progenitor cells
Blood, February 1, 2003; 101(3): 877 - 885.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.